NodThera

In a recent discussion with Jill Drachenberg from BioSpace, Alan Watt, our President & Chief Scientific Officer, highlights NodThera’s innovative approach to addressing chronic neuroinflammation, marking a potential game-changer in Parkinson’s treatment. Our #NLRP3 #inflammasome inhibitors show promise not only in halting brain inflammation in Parkinson’s disease but also in addressing a range of chronic inflammatory conditions, including #obesity and #cardiovascularDisease. Read more here: https://lnkd.in/es_g27ay #NodThera #Neuroinflammation #DrugDiscovery #Biotech

We are excited to share that tomorrow, our Chief Scientific Officer, Alan Watt, will speak at the Future of Healthcare Investment Forum 2024 organized by LSEG (London Stock Exchange Group). He will join an expert panel on Metabolic Diseases to share insights from our pioneering research. Don't miss this opportunity to learn how we are shaping the future of healthcare. Follow this link to register:   https://lnkd.in/dGbknNHf #HealthcareInnovation #MetabolicDiseases #NodThera #FutureOfHealthcare #InvestmentForum2024 #Biotech

Today we reached another exciting clinical milestone in our journey to deliver a paradigm shift in the treatment of chronic inflammatory diseases, announcing positive data from a Phase Ib/IIa #cardiovascular risk study of our lead brain-penetrant #NLRP3 #inflammasone inhibitor candidate, NT-0796. The trial met its primary endpoint, demonstrating a highly statistically significant and rapid reduction of C-reactive protein (CRP), a key biomarker of chronic #cardiometabolic inflammatory diseases, in inflamed obese subjects dosed with NT-0796 compared to placebo. The study also saw reductions in body weight, the most pronounced among high-risk subgroups, supporting the anti-obesity potential of the molecule. Preparations are now underway for a Phase II #obesity study alongside other Phase IIa studies in additional cardiometabolic diseases and #ParkinsonsDisease. Learn more: https://bit.ly/4aYdBPR #NeuroInflammation #DrugDiscovery #Biotech

We are pleased to welcome Daniel Swisher as Chief Executive Officer! Dan joins the team with more than 30 years of leadership expertise in the #LifeSciences industry. During his career, he has led the advancement and commercialization of novel therapeutics in multiple therapeutic areas, including #neuroscience and #RareDiseases, and has significant experience in driving cross function, high-performing teams and relationship building. NodThera’s founder and interim CEO, Alan Watt, becomes our President and CSO, responsible for growing the Company’s R&D organisation and strengthening our world-leading position in #NLRP3 #inflammasome research. Find out more here: https://lnkd.in/d4vYKka7 #Appointment #NewHire #NeuroInflammation #WelcomeToTheTeam

We are pleased to share NodThera’s latest research publication detailing preclinical pharmacology of our clinical-stage drug candidate, NT-0249, establishing its potency and selectivity as an #NLRP3 inhibitor: https://lnkd.in/daSUf7Kb   NT-0249 has been evaluated in animal models demonstrating dose-dependent PK/PD relationships and efficacy in a mouse model of cryopyrin-associated periodic syndrome (CAPS) where it significantly reduced levels of inflammatory biomarkers including IL-1β, thus confirming in vivo target engagement.   Our findings not only underscore the pharmacological potential of NT-0249 but also shed light on the level of target suppression needed for clinical benefit.   Stay tuned for further developments as we continue to innovate for a healthier future!

We're thrilled to announce that our recent publication, "Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the #NLRP3 #Inflammasome Inhibitors NT-0249 and NT-0796," has been selected as the Editor's Choice in March's issue of the Journal of Pharmacology and Experimental Therapeutics (JPET) as well as ranked as the most read article! These recognitions underscore our commitment to groundbreaking research in combating chronic diseases linked to inflammation. Our findings pave the way for new therapeutic strategies in addressing chronic systemic #inflammation, showcasing the potential of our investigational drugs, NT-0249 and NT-0796 , as pivotal in the fight against these conditions.   A heartfelt thank you to our dedicated team and the scientific community for acknowledging our work. Together, we're making strides toward a healthier future.   Stay tuned for further updates as we continue to advance in our mission to revolutionize inflammatory disease treatment. The link to the publication: https://lnkd.in/d28K3d6D

This April, as we observe #Parkinson's Awareness Month, we at NodThera are more committed than ever to our mission of advancing the fight against neuroinflammatory conditions, including Parkinson's disease. Our dedicated team is at the forefront of developing innovative anti-inflammatory therapeutics designed to modulate #NLRP3 #inflammasome activity. We aim not only to alleviate symptoms but also to address the underlying mechanisms of the disease, offering hope for more effective treatments. You can read more about our work here: https://lnkd.in/dGDSYNSC   As we mark this important month, we're reminded of the urgency of our mission and the impact it has on individuals and families affected by Parkinson's. We're inspired by their strength and resilience and motivated by the possibility of making a significant difference in their lives.   Join us in raising awareness about Parkinson's disease and the critical need for innovative treatments. Together, we can make a profound impact.

Following the publication of our #obesity research last month, NodThera features in a new piece in BioCentury Inc., in which Stephen Hansen explores the potential of #NLRP3 #inflammasome inhibitors to enhance cardiometabolic benefits: https://lnkd.in/e8b9VFfG In a landmark study, our compounds, NT-0796 and NT-0249, delivered significant weight loss and extensive cardiometabolic improvements in preclinical models of obesity. NT-0796 is currently progressing in a Phase Ib/IIa #cardiovascular risk trial, targeting CRP levels, a crucial inflammatory marker of #atherosclerotic #cardiovascularDisease risk. #ICYMI #Pharma #DrugDiscovery #Neuroinflammation #Biotech

Breaking news from NodThera ahead of tomorrow's presentation at the AD/PD conference in Lisbon! We are excited to share the positive results from the Phase Ib/IIa trial of our brain-penetrant #NLRP3 #inflammasome inhibitor, NT-0796, in Parkinson’s disease patients who achieved marked reductions in key biomarkers associated with inflammation and neurodegeneration. This breakthrough suggests that NT-0796 may be pivotal in shifting the current treatment landscape toward stopping disease progression through a novel, disease-modifying approach. Discover more at #ADPD2024 and our website: https://lnkd.in/eKMDZjt7   #ParkinsonsResearch #Neuroscience #Innovation #Neuroinflammation

Exciting insights await in the latest Citeline’s Pharma Intelligence podcast episode! Tune in to discover how NodThera is pioneering the field with our CEO, Alan Watt hosted by Lucie Ellis-Taitt. Dive deep into the revolutionary science of our #NLRP3 #Inflammasome inhibitors and their promise against chronic inflammatory diseases, obesity, and neurodegeneration. Witness the transformation of NodThera from a visionary #startup to a trailblazing clinical-stage entity, overcoming the complexities of brain-targeted therapeutics. Plus, get the latest on our Phase Ib/IIa trials targeting obesity-related cardiovascular risks and Parkinson’s disease. To listen to the full #episode: https://lnkd.in/efWdEQZd #DrugDiscovery #ICYMI #Biotech #Pharma #Innovation #Neuroinflammation